Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Issues $800M of Senior Notes

NEW YORK (GenomeWeb) – Thermo Fisher Scientific issued $800 million in aggregate principal amount of 3.3 percent senior notes due in 2022, the company said in a document filed with the US Securities and Exchange Commission on Friday after the close of the market. 

The company announced its plans to offer the dollar-denominated notes and then priced them earlier this month. The company will use net proceeds principally to pay back debt, including the $400 million aggregate principal amount of its 3.25 percent senior notes due 2014 that mature on Nov. 20, it said. The company has also filed a registration document with the SEC for a euro-denominated offering of its senior notes due in 2025. 

The joint book-running managers for the offering are Merrill Lynch, Pierce, Fenner & Smith; Mitsubishi UFJ Securities; Citigroup Global Markets; and Credit Suisse Securities.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.